RxDoctor Payments Data

Tiyashi Choudhury, MD

Family Medicine · Sugar Land, TXNPI 1235497132

Payments from drug & device makers

$4,993in general payments, 2019–2025

Across 324 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$899
  • Abbott$618
  • Lilly USA, LLC$454
  • Pfizer$418
  • GSK$408
  • Amgen$292
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$4,993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,993 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$75,695
Medicare patients
233
Services billed
731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$83,209
OzempicSemaglutide32$40,620
JanuviaSitagliptin Phosphate23$27,823
EliquisApixaban15$20,915
JardianceEmpagliflozin18$20,300
FarxigaDapagliflozin Propanediol12$14,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,166
LinzessLinaclotide11$8,745
Atorvastatin Calcium370$3,554
Rosuvastatin Calcium260$3,286
Levothyroxine Sodium330$3,243
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,007
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,845
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,582
Gabapentin127$2,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$454$83,20978 claims
Novo NordiskOzempic$899$40,62032 claims
MerckJanuvia$58$27,82323 claims
PfizerEliquis$418$20,91515 claims
Boehringer IngelheimJardiance$58$20,30018 claims
AstraZenecaFarxiga$212$14,42412 claims
AbbVieLinzess, Synthroid, Armour Thyroid$215$11,14552 claims
GSKTrelegy Ellipta$408$9,16613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →